Nano-X Imaging Ltd. Stock Price, News & Analysis

NANO-X IMAGING LTD (NASDAQ: NNOX) announced FDA 510(k) clearance for its HealthOST device, an AI software for detailed spinal analysis, particularly in diagnosing vertebral compression fractures and low bone density. This is the tenth FDA clearance for Nanox.AI, enhancing its portfolio aimed at improving musculoskeletal disease detection. HealthOST aims to support clinicians and potentially prevent serious conditions like osteoporosis, affecting over 10 million in the U.S. The device offers precise measurements and automated identification of critical findings.

NANO-X IMAGING LTD (NNOX) has opened a new operational semiconductor chip fabrication plant in Yongin, South Korea. This facility will produce the Nanox.SOURCE chip, critical for the Nanox.ARC system, aiming to democratize access to X-ray technology globally. Covering 12,000 square meters, it is located near a semiconductor cluster, boosting manufacturing capabilities. The company plans to ramp up production by mid-2022, enhancing its vertical integration strategy amidst global supply chain challenges. This facility signifies a pivotal step in providing affordable medical imaging solutions.

NANO-X IMAGING LTD (NASDAQ: NNOX) announced its fourth quarter results for 2021, reporting a revenue of $1.3 million compared to $0 for the same period in 2020. The non-GAAP gross profit stood at $0.2 million. The company strengthened its leadership and completed its technology transfer to Nanox Korea. However, a net loss of $22 million was reported, an increase from $19 million in Q4 2020, driven by merger-related expenses. Cash and equivalents decreased to $88.7 million, down from $213.5 million year-over-year.

Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its fourth quarter and full year results for 2021 on March 31, 2022, before the market opens. CEO Erez Meltzer and CFO Ran Daniel will lead a conference call at 8:30 a.m. ET to discuss the financial results and business updates. Interested parties can join the call by dialing specific numbers or via a webcast link, which will also be available on the Investor Relations section of the Nanox website. The company aims to innovate affordable digital X-ray technology for global medical imaging.

NANO-X IMAGING LTD (Nasdaq: NNOX) announces participation in two investor conferences in March 2022. The Chief Executive Officer, Erez Meltzer, and Chief Financial Officer, Ran Daniel, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15 at 9:20 am EST. They will also attend the Canaccord Genuity Musculoskeletal Conference in Chicago on March 22 at 3:00 pm CT. Webcast links for both presentations will be available on the Company's website.

NANO-X IMAGING LTD (NNOX) has announced a new CPT code from the American Medical Association for its HealthCCSng AI-enabled cardiac imaging solution, effective July 1, 2022. This code promotes the use of AI for detecting coronary artery calcium, a key indicator of cardiovascular disease, enhancing early detection and treatment opportunities. The code aims to streamline workflows for U.S. radiologists and improve patient care. The company has previously secured recognition for AI in imaging, indicating significant progress in medical technology.

NANO-X IMAGING LTD. (NNOX) announced that its subsidiary, USARAD Holdings, Inc., received re-certification from The Joint Commission with the Gold Seal of Approval. This certification underscores USARAD's commitment to high-quality and safe patient care, achieving compliance without conditions in an unannounced inspection. With a robust network of board-certified teleradiologists, USARAD aims to address the global radiologist shortage by integrating AI technology to enhance its imaging services. The company operates under an accelerating demand for outsourced imaging solutions.

NANO-X IMAGING LTD (NASDAQ: NNOX) will conduct a virtual tour of its Nanox.ARC at the RSNA Annual Meeting on December 1, 2021, at 11:30 am EST. The tour will be followed by an investor webinar at 2:00 pm EST the same day. This event will showcase the Nanox.ARC in a clinical setting from Shamir Medical Center, Israel. Interested participants can register for the meeting and will have access to a replay and Q&A session during the webinar.

For more details, visit www.nanox.vision.

NANO-X IMAGING LTD (NASDAQ: NNOX) reported its Q3 2021 results, ending the period with cash and marketable securities of $180.3 million. The company experienced a net loss of $13.5 million, up from $11.1 million in Q3 2020, primarily due to increased R&D and administrative expenses. Highlights include the completion of the Nanox AI merger and acquisitions of USARAD Holdings and MDWEB, aimed at enhancing its imaging technology and analytics capabilities. The company has signed MSaaS agreements for 6,500 Nanox.ARC units and expects to commercialize its technology in 2022.